FOAMIX PHARMACEUTICALS LTD's ticker is FOMX and the CUSIP is M46135105. A total of 4 filers reported holding FOAMIX PHARMACEUTICALS LTD in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $4,688,000 | +93660.0% | 1,407,948 | +90618.3% | 0.00% | – |
| Q3 2019 | $5,000 | +25.0% | 1,552 | 0.0% | 0.00% | – |
| Q2 2019 | $4,000 | -97.6% | 1,552 | -96.6% | 0.00% | – |
| Q1 2019 | $169,000 | +67.3% | 45,244 | +60.4% | 0.00% | – |
| Q4 2018 | $101,000 | +248.3% | 28,207 | +464.1% | 0.00% | – |
| Q3 2018 | $29,000 | -89.4% | 5,000 | -90.8% | 0.00% | – |
| Q2 2018 | $274,000 | +89.0% | 54,580 | +92.3% | 0.00% | – |
| Q1 2018 | $145,000 | – | 28,377 | +141785.0% | 0.00% | – |
| Q2 2017 | $0 | – | 20 | -50.0% | 0.00% | – |
| Q1 2017 | $0 | -100.0% | 40 | -95.2% | 0.00% | – |
| Q3 2016 | $8,000 | -91.8% | 832 | -94.6% | 0.00% | – |
| Q2 2016 | $98,000 | +108.5% | 15,397 | +112.4% | 0.00% | – |
| Q1 2016 | $47,000 | -73.4% | 7,250 | -66.8% | 0.00% | – |
| Q4 2015 | $177,000 | +8.6% | 21,856 | -1.7% | 0.00% | – |
| Q3 2015 | $163,000 | -16.8% | 22,231 | +16.0% | 0.00% | – |
| Q2 2015 | $196,000 | +41.0% | 19,162 | +28.4% | 0.00% | – |
| Q1 2015 | $139,000 | +25.2% | 14,919 | -5.8% | 0.00% | – |
| Q4 2014 | $111,000 | +5450.0% | 15,839 | +3532.8% | 0.00% | – |
| Q3 2014 | $2,000 | – | 436 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DSC Advisors, L.P. | 1,667,377 | $15,440,000 | 9.38% |
| GREAT POINT PARTNERS LLC | 2,769,425 | $25,645,000 | 6.54% |
| Opaleye Management Inc. | 630,000 | $5,834,000 | 3.05% |
| Vivo Capital, LLC | 855,000 | $7,917,000 | 2.47% |
| DAFNA Capital Management LLC | 278,067 | $2,575,000 | 1.79% |
| RA Capital Management | 1,820,138 | $16,854,000 | 1.74% |
| SENZAR ASSET MANAGEMENT, LLC | 523,397 | $4,846,656,000 | 1.25% |
| Perceptive Advisors | 1,373,284 | $12,717,000 | 0.82% |
| Monashee Investment Management LLC | 225,000 | $2,084,000 | 0.73% |
| NEXTHERA CAPITAL LP | 125,000 | $1,158,000 | 0.71% |